Welcome to our dedicated page for Solventum Corporation news (Ticker: SOLV), a resource for investors and traders seeking the latest updates and insights on Solventum Corporation stock.
Solventum Corporation (SOLV) delivers healthcare innovations through material science and digital solutions across MedSurg, Dental, Health IT, and filtration markets. This news hub provides investors and professionals with essential updates on SOLV's strategic developments and operational milestones.
Track official press releases, earnings reports, and regulatory filings in one centralized location. Our curated collection includes updates on wound care advancements, dental technology launches, health information systems, and filtration solutions, offering insights into SOLV's market leadership.
Discover timely information about product innovations like the V.A.C. wound care systems and AI-driven health IT platforms. The page serves healthcare stakeholders needing reliable updates on SOLV's initiatives in surgical solutions, dental attachments, and purification technologies.
Bookmark this resource for streamlined access to SOLV's corporate announcements. Verify facts directly from primary materials while staying informed about this healthcare innovator's progress in transforming patient care through science-driven solutions.
Solventum (NYSE: SOLV) reported third-quarter 2025 results on Nov. 6, 2025: net sales $2.096B (+0.7% reported, +2.7% organic) and GAAP diluted EPS $7.22 (adjusted diluted EPS $1.50). Operating cash flow was $75M and free cash flow was ($22M). Management raised full‑year guidance: organic sales expected at the high end of +2.0%–+3.0% and adjusted EPS to $5.98–$6.08. Solventum launched a 4‑year "Transform for the Future" program targeting ~$500M annual cost savings with ~$500M cumulative pretax costs. Free cash flow guidance revised to $150M–$250M. The company cited tariff impacts, public‑company stand‑up costs, Purification and Filtration divestiture, and segment mix as drivers of results.
Solventum (NYSE: SOLV) said its executives will participate in a fireside chat at the Stifel Healthcare Conference on Wednesday, Nov. 12, 2025, beginning at approximately 11:20 a.m. EST in New York, NY.
A live replay and archived recording will be available on the company's investor website at investors.solventum.com.
Solventum (NYSE: SOLV) appointed Heather Knight as Chief Commercial Officer, effective November 10, 2025. In this newly created role she will oversee global commercial and R&D operations for MedSurg, Dental Solutions and Health Information Systems and will report to CEO Bryan Hanson.
Ms. Knight brings over 30 years of MedTech leadership, most recently serving as COO at Baxter where she led global sales, R&D, supply chain and regulatory affairs. Chris Barry, Executive VP and Group President of MedSurg, will depart effective December 31, 2025. The company said the change does not impact financial guidance and will provide an update with third quarter results in early November.
Solventum (NYSE: SOLV) will report third quarter fiscal 2025 results on Thursday, Nov. 6, 2025, released after U.S. market close. Management will host a live webcast the same day to discuss results and business updates.
Webcast details: Nov. 6, 2025 • 3:30 p.m. CST / 4:30 p.m. EST. Access via https://investors.solventum.com or by phone at US +1 (800) 715-9871, international +1 (646) 307-1963, Conference ID 6342275. A replay, press release, presentation slides, and supplemental financial disclosures will be posted on the Investor Relations website.
Solventum (NYSE: SOLV) has announced the pricing terms for its upsized note tender offers totaling $2.0 billion in aggregate purchase price. The company is offering to purchase multiple series of outstanding notes across two pools: Pool 1 with a maximum amount of $1.5 billion and Pool 2 with a maximum amount of $500 million.
For Pool 1, Solventum expects to accept approximately $650 million of the 5.450% Senior Notes due 2027 (69.35% proration) and $797.3 million of the 5.400% Senior Notes due 2029 (61.24% proration). In Pool 2, about $457.6 million of the 6.000% Senior Notes due 2064 and $21.9 million of the 5.900% Senior Notes due 2054 will be accepted. Settlement is expected on September 10, 2025.
Solventum (NYSE:SOLV) announced modifications to its previously announced tender offers, increasing the aggregate purchase cap from $1.75 billion to $2.0 billion. The company has also increased the Pool 1 Maximum Amount from $1.25 billion to $1.5 billion and raised the Tender SubCap from $500 million to $650 million.
As of the Early Tender Date (September 5, 2025), the offers were significantly oversubscribed. Solventum expects to accept the 5.450% Notes due 2027, 5.400% Notes due 2029, and 5.900% Notes due 2054 for purchase on a prorated basis. Due to oversubscription, the company does not expect to accept any Notes tendered after the Early Tender Date. Settlement is expected on September 10, 2025.
Thermo Fisher Scientific (NYSE: TMO) has completed its acquisition of Solventum's Purification & Filtration business for $4.0 billion in cash. The acquired business, now renamed as Thermo Fisher's Filtration and Separation business, will be integrated into the Life Sciences Solutions segment.
The acquisition strengthens TMO's bioproduction portfolio with advanced filtration technologies and expands its reach into industries requiring ultra-pure water. The acquired business is expected to generate $750 million in revenue for 2025 and achieve mid- to high-single digit organic growth. The transaction is projected to be dilutive to adjusted EPS by $0.06 in the first year, with expected synergies of $125 million in adjusted operating income by year five.
Solventum (NYSE: SOLV) has completed the sale of its Purification & Filtration (P&F) business to Thermo Fisher Scientific (NYSE: TMO) for $4.0 billion in cash. The company will receive net proceeds of $3.4 billion, primarily allocated to debt reduction.
Following this strategic divestiture, Solventum has updated its FY2025 guidance, projecting organic sales growth of 2.0-3.0% and raising its adjusted EPS range to $5.88-$6.03. The company expects operating margins at the high end of 20-21% range and reduced net interest expense of $400 million, down from $450 million previously forecasted.
Solventum (NYSE: SOLV) announced its management's participation in two upcoming investor conferences. The company will attend the 2025 Wells Fargo Healthcare Conference in Boston on September 5, 2025, at 10:15 a.m. EDT, and the Morgan Stanley 23rd Annual Global Healthcare Conference in New York on September 9, 2025, at 10:45 a.m. EDT.
Both fireside chat sessions will be available through live and archived replays on the company's investor relations website at investors.solventum.com.
Solventum (NYSE:SOLV) has launched tender offers to purchase up to $1.75 billion of its outstanding notes. The offers are divided into two pools: Pool 1 with a maximum purchase amount of $1.25 billion covering four series of notes, and Pool 2 with a maximum of $500 million covering two series of notes.
Holders who tender their notes by the Early Tender Date of September 5, 2025, will receive the Total Consideration, which includes an Early Tender Payment of $30 per $1,000 principal amount. The tender offers will expire on September 22, 2025. The Early Settlement Date is expected around September 10, 2025, with the Final Settlement Date around September 25, 2025.
FAQ
What is the current stock price of Solventum Corporation (SOLV)?
What is the market cap of Solventum Corporation (SOLV)?
